Cytokines as predictive biomarkers of alloreactivity

Clinica Chimica Acta; International Journal of Clinical Chemistry
M Brunet

Abstract

Clinical use of valid biomarkers enables the prediction of alloreactive response (risk of rejection) and personal susceptibility to immunosuppressive treatment could lead to personalized immunosuppressive therapy. In clinical transplantation, it has been reported that cytokine production and secretion could be modified by immunosuppressive drugs, as well as during the rejection process. Some cytokines such as interferon (IFN)-γ, interleukin (IL)-2, IL-10, and transforming growth factor (TGF)-β have been identified as candidate biomarkers that correlate with graft outcome and personal response to immunosuppressive agents. This review will focus on the current state of knowledge, indicating that monitoring changes in cytokine production could be used to predict the risk of rejection and to guide immunosuppression therapy in transplant recipients. In addition, many questions regarding the characteristics and standardization of the methods used for cytokine monitoring (ELISA; ELISPOT; Flow Cytometry) that need to be addressed before these assays can be clinically applied will be discussed in light of recent studies showing an association between the expression of some cytokines and genetic variants, the impact of immunosuppression,...Continue Reading

References

Jan 28, 2003·Therapeutic Drug Monitoring·Mario StalderRandall E Morris
Jun 20, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Donald E HricikPeter S Heeger
Sep 3, 2004·Nature Reviews. Immunology·Thomas R Malek, Allison L Bayer
Feb 4, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Michiel C WarléHugo W Tilanus
Feb 16, 2006·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Markus J BartenJan F Gummert
Apr 14, 2006·Kidney International·P Pribylova-HribovaJ Lacha
Aug 21, 2007·Molecular Diagnosis & Therapy·Mercè BrunetOlga Millán
Apr 18, 2008·Journal of the American Society of Nephrology : JASN·Oriol BestardPetra Reinke
Aug 12, 2008·Cell·Ming O Li, Richard A Flavell

❮ Previous
Next ❯

Citations

Mar 8, 2013·Future Medicinal Chemistry·Makio Iwashima, Robert Love
Sep 17, 2014·Biomarkers in Medicine·Jenna F McMinnRoy S Gardner
Oct 8, 2015·Therapeutic Drug Monitoring·Brunet MercèLópez-Hoyos Marcos
Dec 4, 2014·Analytica Chimica Acta·Julie A Stenken, Andreas J Poschenrieder
Aug 7, 2014·Journal of the American Society of Nephrology : JASN·Mark D StegallArthur Matas
Sep 3, 2013·Current Opinion in Organ Transplantation·Clara Crescioli
Sep 3, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Zhiwei ZhangXin Song
Dec 5, 2018·Journal of Immunology Research·Esmaeil MortazGert Folkerts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
Joshua J Augustine, Donald E Hricik
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Olivia M Martinez, Hugo R Rosen
© 2021 Meta ULC. All rights reserved